- Genzyme fails to win FDA approval for MS drug Lemtrada
- Study pinpoints protective genetic mutations for Type 2 diabetes
- Vitals predicts consumer healthcare trends for 2014
- Sanofi creates chief patient officer position
- Study: Potential therapeutic role for aspirin in inhibiting cancerous vestibular schwannoma growth
CAMBRIDGE, Mass. — A drug maker and a hospital have entered an agreement aimed at developing new treatments for various types of hematological malignancies and solid tumors.
Sanofi and Massachusetts General Hospital said their project-based collaboration unites scientists from the respective parties, with the goal of "maximizing the strengths of both academic and industry cross-organizational expertise, and will include both preclinical and clinical translational research to elucidate questions from proof-of-concept to tolerability, efficacy and effectiveness."
The initial agreement is for two years with the option to extend for a longer term at the discretion of both partners. Financial details of the collaboration were not disclosed.
"This is a unique model of collaboration and exemplifies our open innovation [research and devlopment] strategy as well as Sanofi's approach to make the best use of world-class institutions and scientists within greater Boston," said Debasish Roychowdhury, SVP and head of Sanofi Oncology. "Our partners at Massachusetts General Hospital are renowned for their basic and translational oncology research accomplishments and we look forward to leveraging our collective strengths to best develop these molecules."